GENERAL COMMENTS
You should mention what software was used to fit the models and also a bit more detail about what was varied in the sensitivity analysis on page 18. I also noticed a low probability of cost effectiveness for the 1-year time horizon in Table J on page 53 which could be commented on since you mention on page 4, line 29 you are using estimates based only upon one year's worth of trial data so that the more cost effective models (based upon 2+ years data) is using further extrapolations from the one year data you have.
What strengthens this well referenced study is the use of criteria such as the QALY and utilities which are standard in the Bayesian literature and supported by NICE. In addition a lot of effort appears to have gone into obtaining initial values of the large number of parameters used in the Markov model.
This study assesses the cost effectiveness of using nalmefine with psychosocial support to reduce alcohol consumption in high dependent patients and finds that the use of nalmefine reduces diseases and injuries due to alcohol at an acceptable cost over a period of five years using inputs of utilities, transition probabilities of harmful events and costs based upon population values obtained over one year. The outputs are the reduction in avoidable harmful events and an associated calculation of the extra cost of using nalmefine.
The use of Quality of Life per Year (QUALY) as used in this study is a standard criterion supported by NICE and generally accepted in health research as currently the best way to evaluate cost effectiveness. The results are strengthened by also presenting results (page 19 lines 51-56) on how many alcohol-related diseases and deaths can be saved by the use of nalmefene. This latter output is arguably more important that the cost since if a treatment is seen as reducing large numbers of deaths and diseases more money might be thrown at developing programmes to use this treatment and the criterion for cost effectiveness could then be raised from the suggested £20,000.
Page 8, line 8. I am not sure quantitatively how the "continuous high drinking" group were defined? Are these people who had more than a set number of units per week or who had more than tow or three binge sessions per week/month? Page 14. The Personal Risk event should have two parameters (i,x) in the left hand side of equation 1 since it has two inputs event (i) and alcohol consumption (x) mentioned on its right hand side. The risk represents the likelihood of having a harmful event for a given level of alcohol. The mentions of personal risk event in the text on pages 14 and 15 should also therefore have the subscript i as well as x.
Page 15, line 21. Where does the three hours of how long a patient is at risk come from? Is this to do with how long the alcohol stays in a person"s body since the risk of the harmful event is based upon the level of alcohol? Is the length of time that the person is at risk of any relevance since equation 1 (line 45 on page 14) is based solely on how much alcohol the person has consumed and not when or for how long they have been drinking.
Page 17, line 55. What software was used to run the 5000 iterations (simulations) used to fit the models? Is there a reference text or paper which has examples of fitting such complex models to estimate cost effectiveness as fitted here? The model fitting looks to me similar to the sort of Bayesian models that are fitted using the freeware WINBUGS or BUGs (Lunn et al., 2012) . With these models there is usually a burn-in period of say 500 iterations (simulations) prior to running the iterations to estimate the effects (see Lunn et al., 2012) which helps give more robust estimates. Were any iterations used to burn in the models used in this study?
Page 18. Not quite clear what the sensitivity analysis is doing. Are you varying the parameters in prior distributions of the utilities, incidences of diseases, injuries and deaths and resource costs based upon, if possible, outputted confidence intervals of the initially used parameters?
Page 22, line 30. Did you consider looking at incremental costeffectiveness ratios for different types of harmful events such as those given in Table 5 on page 14? This would indicate the relative cost effectiveness of treating each of the harmful events related to alcohol. I also wonder on the breakdown of the causes of the diseases and deaths with respect to Table 5 in page 14. For example how many of the avoidable deaths and diseases (lines 51-56 on page 19) were found by the model to be related to, for example, strokes or how many to heart disease? Are the events in Table 5 (page 14) evenly distributed resulting in equal numbers of diseases, injuries and deaths?
Page 23. A single cost per life year is presented in Table 11 on page 23. I assume since Table 11 mentions in the table footnote an annual adjustment for inflation that this is an average estimation over annual costs over the five year period investigated. Could costs for each of the five years have instead being presented to show how much the costs of namalfene compared to the control treatment increase per year? For example, In Table J on page 53 I notice the probability of spending upto £20,000 per quality of life year (the standard used) is only 35% after one year which appears to suggest that to get the required cost effectiveness the trial or follow-up of patients needs to go on for at least two years. This seems an important point which does not appear to be mentioned in the text especially as (page 4 lines 29-33) the input data is only based upon that single year so there is more doubt about the results of any model for two or more years thereafter (since these are extrapolated) and taking into account the result mentioned earlier from Table J the results for these extrapolated years (2-5) are important in obtaining the desired cost effectiveness which would appear to only kick in after at least two years.
Page 34-41, Table A . Not clear why there are two NMF columns for Abstinence (NMF appears under abstinence in both the fourth and sixth columns from the right).
Page 51. What are the beta1, beta2 and beta3 referred to for some of the variables in the 'parameters for relative risk of harmful events' table? Are they categories?
Pages 51-52. The probability distributions for assumed normally distributed variables do not have any parameter estimates quoted unlike those for the gamma and beta distributions on pages 48-50. Is there a reason for this? I also suspect that the parameters and assumed probability distributions are inputs to the model so could be labelled apriori whereas the other parameters in Table H (pages 46-52) are output so aposteriori. Could you confirm how you decided upon the parameters in the gamma and beta distributions in the rightmost column of Formatting comments:
The article is very well written, but I picked up a couple of typos: P4: line 7 misses "is" P6: line 11 misses "when" after day P13: line 41 misses the end of bracket after table B. P19: line 58, "demonstrates" should be "demonstrated" P28: "consumption" in line 45 can be deleted P29: "to" in line 10 should be "on" P32: line 28, abbreviate the first names of the authors and move them after the surname P25: the Tornado graph isn"t referred to in the text of results.
As a psychosocial researcher, I cannot comment on the economic modelling and validity of the results.
Patient population [page 8, lines 19-22] : it would be good to clarify (this is implied but not clearly stated) that the study population of the economic analysis is a sub-sample of the 3 nalmefene trials, which included, in addition to patients with high/very high DRLs, patients with lower DRLs at baseline. In fact, according to the trial findings, nalmefene was found to be effective in people with high or very high DRLs, but results were not significant in other DRL categories. So, I presume that the economic model used trial data that were specific to the sub-sample of trial participants with high/very high DRLs. This should be clear in the manuscript.
Also: the target population should be reflected in the title and the conclusion of the manuscript and reported in the "strengths and limitations of this study"; moreover, the Discussion section should emphasise that addition of nalmefene to psychosocial support is effective (and cost-effective) in patients with high/very high DRLs at baseline (it currently mentions "nalmefene"s licensed population" without explicitly stating what this is). Or is it assumed that once patients get to such a serious event they either die within the cycle they enter the event, or they survive and remain in this event state without dying later?
Utilities in the short -term phase of the model, page 15, lines 26-37: since "the mean utility difference between the two treatment strategies in the short-term phase of the model [was estimated] using the area between the curves of pooled adjusted mean utility scores", QALYs estimated during the first year are not related to the monthly transition probabilities. Is this correct? Were, then, these monthly transition probabilities over the first year applied only to determine the final % of people in each state entering the longphase model, and also to estimate the % of harmful events during the short-phase of the model?
Utilities of temporary vs. serious harmful event states, page 15, lines 48-58: My understanding is that for temporary harmful events, the authors added a decrement in the utility of the respective DRL state, whereas in serious harmful event states, the authors used the utility corresponding to the specific harmful event, without taking into account the DRL state -is this correct? I agree with the approach, but then shouldn"t the [dis]utilities associated with temporary harmful events be presented as decrements in utility rather than utility values? i.e. wasn"t the final utility dependant on the utility associated with the DRL state at which the temporary harmful event occurred? It doesn"t look so in Table 6 . Contributors, page 30: "PL THB, NR, CK, CB, CF, MT, JBD and FR were responsible for review, analysis and interpretation of the outcomes": I believe FR is JR, plus add a comma after PL.
Data Supplement - Table A: 4 th column from the right shows the total drop-out rate from NMF arm. This is not very clear due to column / heading alignment. Consider moving "Treatment dropout" heading to the left of the cell.
Data Supplement Table H , Parameters for relative risk of harmful events, deaths etc: I presume the probability distribution for relative risks was log-normal rather than normal..? Thank you for your comment. We have added the following to the Sensitivity Analysis section of the Methods:
Relating to PSA "Depending on the model parameter, we based uncertainty around the parameter estimates on calculated or reported patient counts, standard errors or range. Beta and Dirichlet distributions were used for transition probabilities and utility weights, gamma distributions for costs and normal distributions for the regression parameters used in calculating the relative risks of alcohol-attributable harmful events. The distributions used in the PSA for each parameter are given in Data Supplement Table H .
" (P85 L47)
Relating to OSA "Using an approach recommended by Briggs et al. 2012,[43] we based the ranges tested in the OSA on the statistical uncertainty around the estimates using their 95% CI. When a 95% CI was not available for a parameter, we defined a credible range. For parameters close to the population data, a range was defined as the 95% CI assuming that the standard error (SE) was 10% of the mean value, and for parameters based on population sample data the 95% CI assuming a SE of 20% of the mean value was used. For other parameters where statistical uncertainty was not available, we varied estimates by range of interest within credible values informed by clinical practice" (P86 L13)
MethodsSensitivity Analysis
Number Reviewer Comments Response Section 3 Peter Watson I also noticed a low probability of cost effectiveness for the 1-year time horizon in Table J on page 53 which could be commented on since you mention on page 4, line 29 you are using estimates based only upon one year's worth of trial data so that the more cost effective models (based upon 2+ years data) is using further extrapolations from the one year data you have.
Thank you for your comment. We have carried out additional scenario analyses investigating costs and QALYs gained at each year in the model time horizon in Data Supplement Table J and Table K . (P126 and P127)
We have added the following to the Results of the Scenario Analysis Section:
"When considering the scenarios using two-, three-and four-year time horizons, it becomes clear that the cumulative effect of incremental QALYs drives the improvement in cost-effectiveness results with time horizon (see Data Supplement Table J and Table K) . This incremental increase in QALY gain each year of the model time horizon is a result of extrapolation of the superior effectiveness for the nalmefene arm after the first 12 months. No additional incremental difference in effect between treatment arms was given to the compared treatments after the first year." (P93 L48)
We have also added a section on this in the Discussion. Please see comment 13 for more information. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol dependence: a Markov model. bmjopen-2014-005376. This study assesses the cost effectiveness of using nalmefine with psychosocial support to reduce alcohol consumption in high dependent patients and finds that the use of nalmefine reduces diseases and injuries due to alcohol at an acceptable cost over a period of five years using inputs of utilities, transition probabilities of harmful events and costs based upon population values obtained over one year. The outputs are the reduction in avoidable harmful events and an associated calculation of the extra cost of using nalmefine. The use of Quality of Life per Year (QUALY) as used in this study is a standard criterion supported by NICE and generally accepted in health research as currently the best way to evaluate cost effectiveness. The results are strengthened by also presenting results (page 19 lines 51-56) on how many alcohol-related diseases and deaths can be saved by the use of nalmefene. This latter output is arguably more important that the cost since if a treatment is seen as reducing large numbers of deaths and diseases more money might be thrown at developing programmes to use this treatment and the criterion for cost effectiveness could then be raised from the suggested £20,000. Thank you for your comment. The "continuous high drinking" group has been renamed to "no treatment" group throughout the manuscript to make it clearer what this arm is.
Results of the
The use of pre-baseline data to model this arm has been explained more clearly in the manuscript:
In the Methods Overview section: "These were patients deemed eligible for treatment with nalmefene, having high or very high DRLs at baseline. This arm extended the distribution of patients across DRLs recorded in the pre-baseline period of the nalmefene clinical trials over the model time horizon." (P75 L27)
In the treatment efficacy section of the Methods section: "The third "no treatment" arm of continuous high drinkers was modelled using the monthly pre-baseline distributions and drinking characteristics of nalmefene"s licensed population from the nalmefene clinical trials, reproduced for the whole model time horizon. TAC and HDDs taken from the monthly pre-baseline period were used to represent the drinking level and pattern for these patients each month in the model. For the "no treatment" population, the mean number of HDDs was 21.8 and the mean daily TAC was 104 g/day for each month (Error! Reference source not found. Thank you for your comment. We have added a more detailed description of the distributions and ranges used to vary parameters in the one-way sensitivity analysis and probabilistic sensitivity analysis. Please see comment 2 for more information. We have also updated the layout of and footnotes in Table H (see comments 15 and 16).
We also amended the description of the model as a "statistical modelling" in the abstract to "decision modelling". (P70 L13) We also added the following to the Results of the Scenario Analysis section:
"A scenario where all harmful events were removed from the model at a 1-year time horizon resulted in a cost per QALY of £29,142 with 24% probability of costeffectiveness at a £20,000 threshold. This suggests a negligible effect of including these events on the costeffectiveness results at one year. Conversely, excluding these events across a 5-year time horizon caused a more noticeable impact on incremental costs and QALYs compared to the base-case analysis, producing an ICER of £11,530 and 70% probability of costeffectiveness at a £20,000 threshold." (P94 L32)
For the contributions of individual harmful events, the risks of these individual events were modelled using separate baseline population incidences (Data Supplement Table J on page 53 I notice the probability of spending upto £20,000 per quality of life year (the standard used) is only 35% after one year which appears to suggest that to get the required cost effectiveness the trial or followup of patients needs to go on for at least two years. This seems an important point which does not appear to be mentioned in the text especially as (page 4 lines 29-33) the input data is only based upon that single year so there is more doubt about the results of any model for two or more years thereafter (since these are extrapolated) and taking into account the result mentioned earlier from We have added a section on these results to the Discussion:
"A five-year time horizon was chosen to evaluate the cost-effectiveness of nalmefene plus psychosocial support versus psychosocial support alone on the basis that this would be sufficient to capture the longer-term consequences of alcohol dependence, while limiting uncertainty from extrapolating data from the current literature. To consider the impact of this decision, a number of scenario analyses were conducted with different time horizons (Data Supplement Table J ). In the scenario using base-case utilities over a one-year time horizon, nalmefene plus psychosocial support had a low probability (35%) of being cost-effective compared to psychosocial support alone at a £20,000 per QALY decision threshold (although there was an 89% probability of cost-effectiveness over a 1-year time horizon in a scenario using utilities from the real-world STREAM study). On the other hand, scenarios using a time horizon of two years or more had more than 75% probability of being cost-effective at this threshold (Data Supplement I also suspect that the parameters and assumed probability distributions are inputs to the model so could be labelled apriori whereas the other parameters in Table H (pages 46-52) are output so aposteriori.
Could you confirm how you decided upon the parameters in the gamma and beta distributions in the rightmost column of Calculation of the alpha and beta parameters for the gamma and beta distributions is dependent on the format of data available for the parameter being varied. Eg a beta distribution can be parameterised based on the counts of number of events (alpha) and no events (beta) if the data are binomial. If the beta distribution is used when data aren"t binomially distributed, alpha and beta can be calculated based on the mean and standard error using:
An abbreviated summary of the above has been added to The Limitations are underplayed on P4; the 3rd bullet isn"t a limitation, or strength. Authors could use more of the limitations from p27
Thank you for your comment. We have removed point three from this section, and have added the following points to cover the limitations in more detail:
"…Simplifications of certain modelling features when extrapolating patients" trajectories after the trial time horizon represent limitations of the decision model." (P71 L31) "The exploratory "no treatment" arm used to assess the public health benefit of patients beginning treatment for alcohol dependence may not be an accurate representation of the natural evolution of the disease when untreated. The results from this analysis should not be taken at face value but seen as a broad estimation of the benefit of patients entering treatment for alcohol dependence." (P71 L35)
"The generalisability of this study to the UK population may be suboptimal, owing to the fact that the nalmefene clinical trials were multi-national. Furthermore the use of QALYs derived from these trials may not have fully captured the effectiveness of nalmefene." (P71 L44) We also included a section in the Discussion to discuss this further. Please see comment 23 for more information. This is a well-written paper, with a clear study objective and a detailed description of the methods and the results. I have some comments on the content of the manuscript, and some (minor) suggestions on presentation/editing.
Strengths and limitations

MethodsResource Use and Costs
Number
Reviewer comments to the authors:
This is a well-written paper that describes a modelbased economic analysis assessing the cost effectiveness of naltrexone added to psychosocial support versus psychosocial support alone. I have some comments on the content of the manuscript, and some (minor) suggestions on presentation/editing.
Comments on content/study conduct:
Introduction: this is well-written and gives a comprehensive overview of the context. it would be good to clarify (this is implied but not clearly stated) that the study population of the economic analysis is a subsample of the 3 nalmefene trials, which included, in addition to patients with high/very high DRLs, patients with lower DRLs at baseline. In fact, according to the trial findings, nalmefene was found to be effective in people with high or very high DRLs, but results were not significant in other DRL categories. So, I presume that the economic model used trial data that were specific to the sub-sample of trial participants with high/very high DRLs. This should be clear in the manuscript.
Thank you for your comment. We have added the following to the Patient Population section of the Methods:
"The model population was based on a sub-sample of patients from the three nalmefene clinical trials: patients who continued to have a high/very high DRL during the two-week period between baseline and randomisation (Error! Reference source not found.). These patients represent the population that benefits most from treatment with nalmefene, and thus constitute the licensed population for nalmefene." (P75 L36)
Methods -Patient Population
Ifigeneia Mavranezouli
Also: the target population should be reflected in the title and the conclusion of the manuscript and reported in the "strengths and limitations of this study";
Thank you for your comment. The study title has been changed to:
"The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol dependent patients with high/very high DRLs: a Markov model" (P68 L4)
The abstract, "strengths and limitations" and conclusion have also been changed to reflect this, and an additional section discussing the model population has been included in the Discussion (see comment 18).
Title, Discussion
Number Reviewer Comments Response Section 30 Ifigeneia Mavranezouli moreover, the Discussion section should emphasise that addition of nalmefene to psychosocial support is effective (and cost-effective) in patients with high/very high DRLs at baseline (it currently mentions "nalmefene"s licensed population" without explicitly stating what this is).
This sentence has been changed to:
"The objective of this economic analysis was to assess the cost-effectiveness of nalmefene plus psychosocial support versus psychosocial support alone for the treatment of nalmefene"s licensed population (patients with high/very high DRLs at initial assessment and two weeks later)." (P94 L49) Thank you very much for your comment. We have added a paragraph to the Discussion section comparing the nalmefene trial population with patients in the UKATT study. Please see comment 20 for more information.
Discussion
Number
Reviewer
Comments Response Section
Ifigeneia Mavranezouli
Page 7, line 10: the model also includes a "continuous high drinking" arm, which "extended the monthly prebaseline distribution of patients across DRLs recorded in the nalmefene clinical trials over the model time horizon" [page 8, lines 11-14] . First of all, for consistency purposes, I think it would be more appropriate to describe this arm as "no treatment", as "continuous high drinking" is a patient behaviour, not an intervention, and might occur in a sub-group of people regardless of treatment received.
Another issue is, do epidemiological data suggest that people with high/very high DRLs tend to remain in this condition if they do not receive treatment? If data indicate that some of these people do reduce their alcohol consumption overtime and move, for example, to medium DRLs (meaning that they reduce their risk for harmful events), this should be reflected in this arm of the model. Otherwise the benefits of nalmefene in terms of reducing harmful events compared with the "continuous high drinking" arm have been overestimated.
Thank you for your comment. The "continuous high drinking" group has been renamed to "no treatment" group throughout the manuscript to make it clearer what this arm is.
To address your second point, we have included the following in the Discussion:
"While nalmefene plus psychosocial support clearly results in a reduction in harmful events compared to no treatment, this was an exploratory analysis to allow a crude estimation of the likely public health benefit of patients being treated for alcohol dependence. As such, the analysis assumed that patients in the "no treatment" arm remained in a high or very high drinking risk level for the entire time horizon, and did not take into account the possibility that these patients could reduce their level of alcohol consumption without receiving treatment. The number of harmful events occurring with no treatment may therefore have been overestimated." (P95 L48)
Discussion
Ifigeneia Mavranezouli
Treatment efficacy [page 8, last paragraph]: "The BRENDA approach […] was developed specifically for use with medication to promote adherence to treatment": is it possible that the efficacy of nalmefene is partly attributable to concurrent provision of BREDNA, since this is specifically aimed at promoting adherence? Would addition of nalmefene on standard psychosocial treatment offered in UK routine clinical practice have the same relative effect with that reported in the trials? A brief discussion would be useful.
Thank you for your comment. We have added a paragraph to discuss whether BRENDA was an appropriate comparator to the Discussion. Please see comment 23 for more information.
Methods/Discussi on
Number
Reviewer
Comments Response Section
Ifigeneia Mavranezouli
Treatment efficacy [page 9, first paragraph and Table 3 ]: how was this evidence synthesised? It is reported that 2 trials had 6-month time horizons (ESENSE 1 and ESENSE 2) and one had 1-year (SENSE). Did the model utilise data from the 2 ESENSE trials over the first 6-months and from that point and beyond data from the SENSE trial? Or were data from the SENSE trial also pooled with the data from the 2 other trials in order to estimate transition probabilities over the first 6 months of the model? More detail would be useful, possibly in the supplemental file.
Thank you for your comment.
The following has been added as a footnote to Table 4: "Mean estimates or counts of patients based on observed case data from ESENSE 1, ESENSE 2 and SENSE were pooled for the first six months to inform the model DRL health state transition probabilities, and utility values for the DRL health states. Following the first six months, data from SENSE were used up to 1 year, after which data from this study were extrapolated to the 5 year time horizon." (P80 L45)
The following has been added as a footnote to Table 6 : "A mixed model repeated measures analysis was carried out using EQ-5D utilities and observed case data from all three trials to estimate treatment effect for the first six months. The model used an unstructured covariance matrix and included country, sex, time (months 1-6) and treatment as fixed effects, as well as baseline value-bytime and treatment-by-time interactions." (P85 L19) Table 5 , page 14: "absorbing state" implies a state that cannot progress further -couldn"t people in these serious, harmful event states move to the "death" state later in time (e.g. two years later)? Or is it assumed that once patients get to such a serious event they either die within the cycle they enter the event, or they survive and remain in this event state without dying later?
Methods
Thank you for your comment. Patients experiencing serious events were able to transition to the death state due to general mortality, therefore we have changed the manuscript to refer to these as "serious event states" rather than "absorbing states".
A footnote has also been added to Table 5 Utilities in the short -term phase of the model, page 15, lines 26-37: since "the mean utility difference between the two treatment strategies in the short-term phase of the model [was estimated] using the area between the curves of pooled adjusted mean utility scores", QALYs estimated during the first year are not related to the monthly transition probabilities. Is this correct? Were, then, these monthly transition probabilities over the first year applied only to determine the final % of people in each state entering the long-phase model, and also to estimate the % of harmful events during the short-phase of the model?
Thank you for your comment. QALYs estimated in the first year were not related to the monthly transition probabilities. Monthly transition probabilities were therefore only used to determine: Utilities of temporary vs. serious harmful event states, page 15, lines 48-58: My understanding is that for temporary harmful events, the authors added a decrement in the utility of the respective DRL state, whereas in serious harmful event states, the authors used the utility corresponding to the specific harmful event, without taking into account the DRL state -is this correct? I agree with the approach, but then shouldn"t the [dis]utilities associated with temporary harmful events be presented as decrements in utility rather than utility values? i.e. wasn"t the final utility dependant on the utility associated with the DRL state at which the temporary harmful event occurred? It doesn"t look so in Table 6 .
Thank you for your comment. We have updated the description of harmful event utilities in the Methods section:
"During the short-term phase of the model, for both temporary and serious harmful events, patients incurred event-related utility decrements (and the addition of event-related costs) applied to the utilities (and costs) incurred independently by their DRL health states (Error! Reference source not found. Table 9 , page 20: it is noted that, although NMF in addition to psychosocial support (PS) considerably reduces the number of harmful events and associated costs compared with CHD, the reduction is mainly attributable to the provision of PS. This should be reported in the text, possibly in the relevant paragraph in discussion (page 26, lines 38-43 and end of paragraph). In fact, PS and not CHD is the relevant comparator for measuring reduction in harmful events and associated costs, given that PS appears to reflect standard practice in the UK (according to page 7, lines 45-51).
Thank you for your comment. The following has been added to the discussion section:
"The reduction in number of harmful events with nalmefene plus psychosocial support compared to no treatment appears to be mostly due to the provision of psychosocial support (Table 10) ; however, this observation may be due to overestimation of the number of harmful events occurring with "no treatment" compared to the other treatment arms. As stated previously, the comparison with a "no treatment" arm was intended as an exploratory analysis, and psychosocial support should be considered a more relevant comparator to nalmefene than "no treatment", in alignment with current practice in the UK." (P96 L4) Table 10 , page 22: the table may be confusing for some readers, as the differences in the numbers of events refer to 100,000 patients, but cost differences are reported per patient. Also: it should be made clear that these costs relate to harmful events only (i.e. they do not include treatment costs).
Thank you for your comment. An additional row has been added to Table 10 for costs per 100,000 patients.
A footnote has also been added: "*Differences in costs are those incurred as a result of differences in harmful events only" (P90 L28) Thank you for your comment. This sentence has been amended to:
"In addition, the analysis aimed to demonstrate the public health benefit of reducing alcohol consumption and the value for the healthcare system of patients entering treatment for alcohol dependence." (P94 L51)
Discussion
Ifigeneia Mavranezouli
Contributors, page 30: "PL THB, NR, CK, CB, CF, MT, JBD and FR were responsible for review, analysis and interpretation of the outcomes": I believe FR is JR, plus add a comma after PL.
Thank you for your comment. These corrections have been implemented.
FootnotesContributors
Ifigeneia Mavranezouli
Data Supplement - Table A: 4th column from the right shows the total drop-out rate from NMF arm. This is not very clear due to column / heading alignment. Consider moving "Treatment dropout" heading to the left of the cell.
Thank you for your comment. Table A has been reformatted to clarify that the NMF column refers to total drop-out for the nalmefene arm. (P106)
Page 27-28: "This incremental increase in QALY gain each year of the model time horizon is a result of extrapolation of the superior effectiveness for the nalmefene arm after the first 12 months. No additional incremental difference in effect between treatment arms was given to the compared treatments after the first year". Considering a superior effectiveness of nalmefene that is retained beyond the first 12 months and up to 5 years may be considered a strong assumption. What would happen if you kept a 5-year time horizon but assumed that the nalmefene effect is not retained beyond 12 months? [i.e. transition probabilities would be the same for the two treatment options beyond 12 months, but final proportions of patients in each state at end of first year would be different, still favouring nalmefene]. This scenario would likely improve the cost effectiveness of nalmefene compared with the 1-year time horizon analysis (the ICER of which is roughly £24.5K/QALY) and, although somewhat conservative, it would be more realistic than the assumption that nalmefene retains its effectiveness unchanged over 5 years.
Thank you very much. This is a very relevant comment that allows us to be clearer and extend the description of the model post-trial extrapolation; the model having been constructed in the way you propose in your comment.
The Results section was amended as follows: "This incremental increase in QALY gain each year of the model time horizon is a result of the superior effectiveness for the nalmefene arm gained during the first 12 months. During this phase, patients in the nalmefene arm exhibited reduced alcohol consumption compared to those in the psychosocial support arm, thus when the longterm phase of the model began there was a higher proportion of patients in the controlled drinking state, and a lower proportion of patients in the high/very high DRL health state for nalmefene plus psychosocial support than for psychosocial support alone. With the exception of the medium DRL health state (Data Supplement Table  B ), no additional difference in treatment benefit between the arms was considered beyond the retained differences in proportions of patients in the different health states after the first 12 months. Although treatment-specific transition probabilities were used for the long-term medium DRL health state, the model results were insensitive to this feature when tested in an extreme scenario against nalmefene where all patients in the medium DRL health state at the end of 12 months transitioned to the high and very high DRL state if they were in the nalmefene arm, or to the controlled drinking state if they were in the comparator arm."
The Discussion section was amended as follows: "For conservative modelling, the incremental effectiveness between the two treatment arms gained during the first 12 months was retained for the remainder of the model time horizon, represented by the difference at 12 months in the number of patients that had responded to treatment between the compared arms. However, with the exception of the medium DRL health state, no additional differential effect per se
Page 26 Page 30
Reviewer Comments Response Section between the treatment arms was considered to arise after 12 months. For the medium DRL health state, transition probabilities were extrapolated from the first year of the model and therefore differed between treatment arms (Data Supplement Table  B) . Nevertheless, only a small proportion of patients were in this health state for either treatment arm after the first year, and testing this assumption with an extreme scenario that was unfavourable to nalmefene indicated that the model results were insensitive to this model feature." We have also amended for more precision one section of the discussion.
This amendment to the Discussion section is as follow:
"While it could be argued that BRENDA, as used during the nalmefene clinical trials, is not representative of best recommended practice in the UK according to NICE clinical guideline 115 (which recommends cognitive behavioural therapies, behavioural therapies or social network and environment-based therapies as first-line treatment for mild alcohol dependence, aligned with the licensed population for nalmefene),[8 9] BRENDA was deemed by clinical experts to be sufficiently similar to "extended brief psychosocial intervention", the type of psychosocial intervention used most frequently for patients assessed in standard UK practice, which supports its validity as the main comparator to nalmefene in this model. [32] Furthermore, a reduction in alcohol consumption was observed with the BRENDA plus placebo arm in the nalmefene trials, therefore it does appear to be effective as psychosocial intervention for mild alcohol-dependent harmful drinkers.[14 15]"
